CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Lithium aspartatedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06099886
NCT06099886Phase 1Completed
CompareCT.gov

Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Phase I Trial

State University of New York at Buffalo·interventional·Posted Oct 25, 2023·Updated May 13, 2026

In Brief

A Phase 1 clinical trial evaluating Lithium aspartate for Parkinson's Disease. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS)

Timeline

Phase 1CompletedFinished
202420252026
First PostedOct 25, 2023
Enrollment StartOct 12, 2023
Primary CompletionDec 6, 2024
Study CompletionApr 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.7 years ago

Interventions

Lithium aspartatedietary

Lithium aspartate 30-45mg/day